Search

Your search keyword '"Hierro, C."' showing total 259 results
Start Over Author "Hierro, C."
259 results on '"Hierro, C."'

5. 107P Unveiling mismatch repair deficiency (dMMR) and microsatellite-instability high (MSI-H) detection in cancer patients (pt) using a next-generation sequencing (NGS)-based molecular pre-screening program (MPP)

Author

Rincon, L. Notario, Bergamino, M.A., Ochoa de Olza Amat, M., Carcereny, E., Urbizu, A., Muñoz-Mármol, A.M., Arnaldo, L., Azuara, D., Badosa, A. Alay, Matias-Guiu, X., Jimeno, M., Hernandez, A., Balaña, D., Planas, C. Fina, Martín, M. Gil, Castillo, J.J. Soto, Martin-Liberal, J., Lazaro, C., Sanz, C., and Hierro, C.

Published
2023
Full Text
View/download PDF

7. Isquemia mesentérica: manejo endovascular

Author

Hernán Aste S, Napoleón Delgado S, Juan Carlos del Hierro C, Akira Tsuha A, Pilar Cabrera M, and Luis Bracamonte O

Subjects
General Medicine
Abstract

La isquemia mesentérica es una condición que puede volverse muy grave y ser letal, más aún en los casos agudos. Un tratamiento precoz es muy importante. Se presentaron cuatro casos consecutivos tratados por nuestro equipo con trombosis, o disección o aneurismas de arterias mesentérica superior y tronco celíaco, se revisaron las indicaciones y se evaluaron los tratamientos llevados a cabo. Se utilizaron procedimientos endovasculares en todos, técnicamente en forma exitosa, evitando que progrese a un desenlace peligroso. Hubo diversidad de técnicas endovasculares adaptándolas a cada caso. En ningún paciente se requirió un acceso quirúrgico abierto para completar el tratamiento realizando las intervenciones prontas. El manejo endovascular de las lesiones mesentéricas es factible y replicable, y en nuestros casos podría haber prevenido una necrosis intestinal así como la necesidad de cirugías resectivas.

Published
2021
Full Text
View/download PDF

9. Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study

Author

Meric-Bernstam, F, Bahleda, R, Hierro, C, Sanson, M, Bridgewater, J, Arkenau, H-T, Tran, B, Kelley, RK, Park, JO, Javle, M, He, Y, Benhadji, KA, Goyal, L, Meric-Bernstam, F, Bahleda, R, Hierro, C, Sanson, M, Bridgewater, J, Arkenau, H-T, Tran, B, Kelley, RK, Park, JO, Javle, M, He, Y, Benhadji, KA, and Goyal, L

Abstract

Futibatinib, a highly selective, irreversible FGFR1-4 inhibitor, was evaluated in a large multihistology phase I dose-expansion trial that enrolled 197 patients with advanced solid tumors. Futibatinib demonstrated an objective response rate (ORR) of 13.7%, with responses in a broad spectrum of tumors (cholangiocarcinoma and gastric, urothelial, central nervous system, head and neck, and breast cancer) bearing both known and previously uncharacterized FGFR1-3 aberrations. The greatest activity was observed in FGFR2 fusion/rearrangement-positive intrahepatic cholangiocarcinoma (ORR, 25.4%). Some patients with acquired resistance to a prior FGFR inhibitor also experienced responses with futibatinib. Futibatinib demonstrated a manageable safety profile. The most common treatment-emergent adverse events were hyperphosphatemia (81.2%), diarrhea (33.5%), and nausea (30.4%). These results formed the basis for ongoing futibatinib phase II/III trials and demonstrate the potential of genomically selected early-phase trials to help identify molecular subsets likely to benefit from targeted therapy. SIGNIFICANCE: This phase I dose-expansion trial demonstrated clinical activity and tolerability of the irreversible FGFR1-4 inhibitor futibatinib across a broad spectrum of FGFR-aberrant tumors. These results formed the rationale for ongoing phase II/III futibatinib trials in cholangiocarcinoma, breast cancer, gastroesophageal cancer, and a genomically selected disease-agnostic population.This article is highlighted in the In This Issue feature, p. 275.

Published
2022

10. Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies

Author

Cucurull M, Notario L, Sanchez-Cespedes M, Hierro C, Estival A, Carcereny E, and Saigí M

Subjects
PD-L1, ICI, STK11, KRAS, NSCLC
Abstract

Approximately 20% of lung adenocarcinomas harbor KRAS mutations, an oncogene that drives tumorigenesis and has the ability to alter the immune system and the tumor immune microenvironment. While KRAS was considered "undruggable" for decades, specific KRAS G12C covalent inhibitors have recently emerged, although their promising results are limited to a subset of patients. Several other drugs targeting KRAS activation and downstream signaling pathways are currently under investigation in early-phase clinical trials. In addition, KRAS mutations can co-exist with other mutations in significant genes in cancer (e.g., STK11 and KEAP1) which induces tumor heterogeneity and promotes different responses to therapies. This review describes the molecular characterization of KRAS mutant lung cancers from a biologic perspective to its clinical implications. We aim to summarize the tumor heterogeneity of KRAS mutant lung cancers and its immune-regulatory role, to report the efficacy achieved with current immunotherapies, and to overview the therapeutic approaches targeting KRAS mutations besides KRAS G12C inhibitors.

Published
2022

11. Results of the interprofessional and interdisciplinary Berlin round table on patient-reported outcomes, quality of life, and treatment expectations of patients with gynecological cancer under maintenance treatment

Author

Armbrust, R, Alavi, S, Pirmorady, A, Chen, F, Colombo, N, Gultekin, M, Hierro, C, Lemley, B, Mirza, M, Urkmez, E, Fotopoulou, C, Vinzent, J, Gonzalez Martin, A, Krull, A, Heepe, J, Rose, M, Sehouli, J, Armbrust R., Alavi S., Pirmorady A., Chen F., Colombo N., Gultekin M., Hierro C., Lemley B., Mirza M. R., Urkmez E., Fotopoulou C., Vinzent J., Gonzalez Martin A., Krull A., Heepe J., Rose M., Sehouli J., Armbrust, R, Alavi, S, Pirmorady, A, Chen, F, Colombo, N, Gultekin, M, Hierro, C, Lemley, B, Mirza, M, Urkmez, E, Fotopoulou, C, Vinzent, J, Gonzalez Martin, A, Krull, A, Heepe, J, Rose, M, Sehouli, J, Armbrust R., Alavi S., Pirmorady A., Chen F., Colombo N., Gultekin M., Hierro C., Lemley B., Mirza M. R., Urkmez E., Fotopoulou C., Vinzent J., Gonzalez Martin A., Krull A., Heepe J., Rose M., and Sehouli J.

Abstract

Background Patients' reported outcomes and their perspectives around their therapeutic management is a field of continuously increasing relevance in gynecological oncology. We report the results of the Berlin dialog on seven patient-reported parameters and outcomes concerning chemotherapy and maintenance treatment in patients with gynecological cancer. Methods Key opinion leaders in gynecological oncology from different European counties and representatives of leading patients' advocate groups in Berlin held a consensus meeting in Berlin on April 6, 2019. Seven topics of interest were identified in advance around quality of life, iatrogenic toxicity, treatment decision-making processes, sexuality, participation in clinical trials, second opinion, and long-term survivors with the the following standard operating procedure for processing and discussion: (1) agreement on its relevance; (2) literature review, and (3) discussion and consensus statements. Results All main topics reached a consensus approval. The defined statements emphasized the importance of patients' role in incorporating and establishing quality of life as an outcome parameter in clinical trials. Furthermore, discussants raised the importance of identifying new tools for reflecting patient-reported iatrogenic toxicity as well as emphasizing patients' rights in providing personal information, access to second opinion in the decision-making process, and their participation in clinical trials. Conclusion The results of this round table meeting could help redefine perspectives on the discussed topics and the importance for therapeutic management as well as for trial designs.

Published
2020

13. 1508MO Rationalizing the use of off-label drugs (OLD) within a special medication (ME) program for cancer patients (pt): The Catalan Institute of Oncology (ICO) prognostic score (ICO MEscore)

Author

Notario Rincon, L., primary, Hierro, C., additional, Esteve, A., additional, Fontanals, S., additional, González, A., additional, Loureiro, E., additional, Sun, C., additional, Margelí, M., additional, Moran, T., additional, Font, A., additional, Manzano, J.L., additional, Balaña, C., additional, Quiroga, V., additional, Quer, N., additional, Ibañez, C., additional, Martínez-Benavides, J., additional, Brunet, J., additional, Clopes, A., additional, and Mesia, R., additional

Published
2021
Full Text
View/download PDF

14. 575TiP Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multicohort phase II trial (CABATEN trial / GETNE-T1914)

Author

Grande, E., primary, Garcia-Carbonero, R., additional, Teule, A., additional, Benavent Viñuales, M., additional, Jimenez-Fonseca, P., additional, Molina-Cerrillo, J., additional, López, C., additional, Custodio, A., additional, Hierro, C., additional, Gallego, J., additional, Alonso, V., additional, Carmona-Bayonas, A., additional, Llanos, M., additional, Sevilla, I., additional, Hernando, J., additional, Lista, F., additional, Antón Pascual, B., additional, Ruffinelli, J.C., additional, Gallego Jiménez, I., additional, and Capdevila, J., additional

Published
2021
Full Text
View/download PDF

19. 1712P Implementation of a molecular pre-screening program (MPP) in a network of public cancer centres for phase I clinical trial (Ph1-CT) candidates: The PREICO program

Author

Soto Castillo, J.J., Notario Rincon, L., Azuara, D., Ruffinelli, J.C., Stradella, A., Oliva Bernal, M., Calvo Campos, M., Jové, M., Llop Serna, S., Villanueva Vazquez, R., Cuadra Amor, C., Bergamino, M.A., Teixidor Vilà, E., Villatoro Gómez, S., González Acosta, M., Fina Planas, C., Hierro, C., Gil Martín, M., Lazaro, C., and Martin-Liberal, J.

Published
2023
Full Text
View/download PDF

20. 1056P Efficacy of spartalizumab across multiple cancer types in patients with PD1-high mRNA expressing tumors (SOLTI-1904 ACROPOLI)

Author

Prat, A., Pascual, T., Juan, M., Paz-Ares, L., Felip, E., Garralda, E., Gonzalez-farre, B., Arance Fernandez, A.M., Martin-Liberal, J., López, A., Izarzugaza Peron, Y., Garcia-Corbacho, J., Saura Manich, C., Hierro, C., Sanfeliu Torres, E., Cejalvo, J.M., Salvador, F., Mesia Nin, R., Cervantes, A., and Tabernero, J.

Published
2023
Full Text
View/download PDF

21. 723O Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multi-cohort basket phase II trial (CABATEN/GETNE-T1914)

Author

Castillon, J. Capdevila, Molina-Cerrillo, J., Viñuales, M. Benavent, Garcia-Carbonero, R., Teule, A., Custodio, A., Jimenez-Fonseca, P., López, C., Hierro, C., Carmona-Bayonas, A., Martínez-Trufero, J., Llanos, M., Sevilla, I., Hernando, J., Alonso-Gordoa, T., Jimenez, I. Gallego, Gallego, J., Pascual, B. Antón, and Grande, E.

Published
2023
Full Text
View/download PDF

24. Can we improve patient selection for phase I clinical trials (phI1) based on immuno-oncology score prognostic index (VIO)?

Author

Matos Garcia, I., primary, Hierro, C., additional, Martin-Liberal, J., additional, VIAPLANA, C., additional, Azaro, A., additional, Brana, I., additional, Vieito Villar, M., additional, Saavedra, O., additional, Gardeazabal, I., additional, Ros, J., additional, Prieto, P., additional, Berché, R., additional, Muñoz-Couselo, E., additional, Oliveira, M., additional, Elez Fernández, E., additional, Felip, E., additional, Carles, J., additional, Tabernero, J., additional, Dienstmann, R., additional, and Garralda, E., additional

Published
2019
Full Text
View/download PDF

25. Immune checkpoint inhibitors (ICIs) as “chemotherapy (Ctx) sensitization” strategy in advanced solid tumours

Author

Montana, F J Ros, primary, Matos, I., additional, Vilacampa, G., additional, Azaro, A., additional, Martin-Liberal, J., additional, Hierro, C., additional, Brana, I., additional, Viaplana, C., additional, Villar, M Vieito, additional, Gardeazabal, I., additional, Saura, C., additional, Madrid, L Fariñas, additional, Mercade, T Macarulla, additional, Saavedra, O., additional, Pardo, N., additional, de Olza, M Ochoa, additional, Muñoz-Couselo, E., additional, Tabernero, J., additional, Dienstmann, R., additional, and Garralda, E., additional

Published
2019
Full Text
View/download PDF

27. Validation of the VIO prognostic index in patients with metastatic urothelial carcinoma treated with immune-checkpoint inhibitors

Author

Morales Barrera, R., primary, Matos, I., additional, Gonzalez, M., additional, Suárez, C., additional, Ros, J., additional, Valverde, C., additional, Fernandez, C., additional, Hierro, C., additional, Serra, E., additional, Mateo, J., additional, Gutierrez, S., additional, Martín Liberal, J., additional, Quintana, A., additional, Dienstmann, R., additional, Serrano, C., additional, Garralda, E., additional, and Carles, J., additional

Published
2019
Full Text
View/download PDF

28. Artificial intelligence combining radiomics and clinical data for predicting response to immunotherapy

Author

Ligero, M., primary, Garcia-Ruiz, A., additional, Viaplana, C., additional, Raciti, M.V., additional, Matos, I., additional, Liberal, J Martín, additional, Hierro, C., additional, Gonzalez, M., additional, Barrera, R Morales, additional, Suárez, C., additional, Elez, E., additional, Brana, I., additional, Muñoz-Couselo, E., additional, Oaknin, A., additional, Felip, E., additional, Tabernero, J., additional, Carles, J., additional, Dienstmann, R., additional, Garralda, E., additional, and Lopez, R Perez, additional

Published
2019
Full Text
View/download PDF

29. Integration of a Monitoring System of Climatic Conditions to the National Energy Management System.

Author

del Hierro, C. A., Enríquez, J. C., Sánchez, R. G., and Panchi, D.

Subjects
ENERGY management, DATA acquisition systems, SYSTEM integration, ORTHOGONAL functions, ELECTRIC power consumption, DATA mining
Abstract

Copyright of Revista Técnica Energía is the property of Centro Nacional de Control de Energia CENACE and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2021

30. Characterization and simulation of dynamic phenomena related to the operation of an electric arc furnace connected to the electric power system of Ecuador.

Author

Cepeda, J. C. and Del Hierro, C. A.

Subjects
ELECTRIC power systems, ARC furnaces, ELECTRIC furnaces, ELECTRIC arc, DYNAMIC simulation, PULSE width modulation, PULSE width modulation transformers
Abstract

Copyright of Revista Técnica Energía is the property of Centro Nacional de Control de Energia CENACE and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2021

31. Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi’s

Author

Tran, B., primary, Meric-Bernstam, F., additional, Arkenau, H.-T., additional, Bahleda, R., additional, Kelley, R.K., additional, Hierro, C., additional, Ahn, D., additional, Zhu, A., additional, Javle, M., additional, Winkler, R., additional, He, H., additional, Huang, J., additional, and Goyal, L., additional

Published
2018
Full Text
View/download PDF

32. Refining criteria of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) to improve clinical applicability

Author

Matos Garcia, I., primary, García Ruiz, A., additional, Martin-Liberal, J., additional, Hierro, C., additional, Ochoa De Olza Amat, M., additional, Viaplana, C., additional, Mur, G., additional, Vieito Villar, M., additional, Brana, I., additional, Azaro, A., additional, Perez, C., additional, Rodriguez Freixinos, V., additional, Argiles, G., additional, Oliveira, M., additional, Felip Font, E., additional, Muñoz-Couselo, E., additional, Tabernero, J., additional, Dienstmann, R., additional, and Garralda, E., additional

Published
2018
Full Text
View/download PDF

33. Tumor infiltrating lymphocytes (TILs) and PDL1 expression as prescreening enrichment biomarkers of clinical benefit to immune checkpoint inhibitors (CI) in early clinical trials (ECT)

Author

Martin-Liberal, J., primary, Pagliuca, F., additional, Hierro, C., additional, Viaplana, C., additional, Muñoz Couselo, E., additional, Capdevila, J., additional, Matos, I., additional, Fariñas Madrid, L., additional, Zamora, E., additional, Braña Garcia, I., additional, Elez Fernandez, E., additional, Ochoa De Olza Amat, M., additional, Azaro, A., additional, Alsina, M., additional, Vieito Villar, M., additional, Fasani, R., additional, Tabernero, J., additional, Garralda, E., additional, Dienstmann, R., additional, and Nuciforo, P.G., additional

Published
2018
Full Text
View/download PDF

34. Vall d’Hebron Institute of Oncology (VHIO) immuno-oncology prognostic index (VIO): A new tool for improved patient (pt) selection in phase I (Ph1) trials with immune checkpoint inhibitors (ICI)

Author

Hierro, C., primary, Matos, I., additional, Martin-Liberal, J., additional, Ochoa De Olza Amat, M., additional, Felip, E., additional, Costa Rivas, M., additional, Vieito Villar, M., additional, Brana, I., additional, Azaro, A., additional, Perez-Gago, M.C., additional, Gros, A., additional, Carles, J., additional, Oaknin, A., additional, Macarulla, T., additional, Saura, C., additional, pardo, N., additional, Muñoz-Couselo, E., additional, Tabernero, J., additional, Dienstmann, R., additional, and Garralda, E., additional

Published
2018
Full Text
View/download PDF

35. Immune prognostic index (IPI) and hyper-progressive disease (HPD) in patients (pts) exposed to targeted agents (TAs) in phase I trials (Ph1T): Can lessons from immune checkpoint inhibitors (ICIs) be translated to other scenarios?

Author

Matos Garcia, I., primary, Azaro, A., additional, Viaplana, C., additional, Hierro, C., additional, Martin-Liberal, J., additional, Brana, I., additional, Gardeazabal, I., additional, Gomila, P., additional, Vieito Villar, M., additional, Ochoa De Olza Amat, M., additional, Elez Fernandez, E., additional, Oliveira, M., additional, Oaknin, A., additional, Verdaguer, H., additional, Navarro Mendivil, A., additional, Alsina, M., additional, Tabernero, J., additional, Macarulla Mercade, T., additional, Dienstmann, R., additional, and Garralda, E., additional

Published
2018
Full Text
View/download PDF

36. Impact of a molecular prescreening program (MPP) in the management of patients with non-glioblastoma brain tumors

Author

Benítez Montañez, J.C., primary, Vieito Villar, M., additional, Hierro, C., additional, Gonzalez Rodriguez, M., additional, Matos, I., additional, Braña Garcia, I., additional, Suarez Rodriguez, C., additional, Martinez Saez, E.A., additional, Perez-Gago, M.C., additional, Morales-Barrera, R., additional, Ortiz, C., additional, Suarez, C., additional, Maldonado, X., additional, Martinez-Ricarte, F., additional, Auger, C., additional, Azaro, A., additional, Dienstmann, R., additional, Carles, J., additional, and Garralda, E., additional

Published
2018
Full Text
View/download PDF

37. Phase III KEYNOTE-590 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer

Author

Kato, K., primary, Shah, M.A., additional, Enzinger, P.C., additional, Bennouna, J., additional, Shen, L., additional, Adenis, A., additional, Sun, J.-M., additional, Cho, B.C., additional, Ozguroglu, M., additional, Kojima, T., additional, Kostorov, V., additional, Hierro, C., additional, Zhu, Y., additional, Shah, S., additional, Bhagia, P., additional, and Doi, T., additional

Published
2018
Full Text
View/download PDF

39. Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors

Author

Meric-Bernstam, F., primary, Arkenau, H., additional, Tran, B., additional, Bahleda, R., additional, Kelley, R., additional, Hierro, C., additional, Ahn, D., additional, Zhu, A., additional, Javle, M., additional, Winkler, R., additional, He, H., additional, Huang, J., additional, and Goyal, L., additional

Published
2018
Full Text
View/download PDF

40. A phase 3 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590 - Trial in progress

Author

Kato, K., primary, Shah, M., additional, Enzinger, P., additional, Bennouna, J., additional, Shen, L., additional, Adenis, A., additional, Sun, J., additional, Cho, B., additional, Ozguroglu, M., additional, Kojima, T., additional, Kostorov, V., additional, Hierro, C., additional, Zhu, Y., additional, Shah, S., additional, Bhagia, P., additional, and Doi, T., additional

Published
2018
Full Text
View/download PDF

41. FGFR 360° resistance: Establishing a translational research framework in FGFR-altered (FGFRalt) patients (pt) treated with fibroblast growth factor receptor inhibitors (FGFRinh)

Author

Hierro, C., primary, Sánchez-Guixé, M., additional, Ruiz-Pace, F., additional, Jimenez, J., additional, Maynes, L., additional, Azaro, A., additional, Martin-Liberal, J., additional, Ochoa de Olza, M., additional, Braña, I., additional, Vieito, M., additional, Villanueva, A., additional, Palmer, H.G., additional, Arribas, J., additional, Nuciforo, P., additional, Vivancos, A., additional, Garralda, E., additional, Dienstmann, R., additional, Tabernero, J., additional, Serra, V., additional, and Rodon, J., additional

Published
2017
Full Text
View/download PDF

42. Outcomes of malignant pleural mesothelioma (MPM) patients (p) treated with immune-oncology drugs (IO) in clinical trials

Author

Cedres, S., primary, Martinez Marti, A., additional, Navarro, A., additional, Pardo, N., additional, Remon, J., additional, Matos, I., additional, Ochoa de Olza, M., additional, Hierro, C., additional, Martin Liberal, J., additional, Miquel, J.M., additional, Viaplana, C., additional, Villacampa Javierre, G., additional, Dienstmann, R., additional, and Felip Font, E., additional

Published
2017
Full Text
View/download PDF

48. First-in-human phase I trial of the anti-CEACAM5 antibody–drug conjugate SAR408701 in patients with advanced solid tumors (NCT02187848)

Author

Gazzah, A., primary, Stjepanovic, N., additional, Ryu, M.H., additional, Tabernero, J., additional, Soria, J.C., additional, Bedard, P., additional, Kang, Y.K., additional, Bahleda, R., additional, Guillemin-Paveau, H., additional, Henry, C., additional, Hatteville, L., additional, Zilocchi, C., additional, Demers, B., additional, and Hierro, C., additional

Published
2016
Full Text
View/download PDF

49. Early interventions to detect potential drug–drug interactions on patient eligibility for phase 1 clinical trials

Author

Azaro, A., primary, Ghiglione, L., additional, Valdivia, C., additional, Munné, M., additional, Renedo, B., additional, Sabaté, N., additional, Alcalde, M., additional, Braña, I., additional, Hierro, C., additional, Martin-Liberal, J., additional, Ochoa de Olza, M., additional, Argiles Martínez, G., additional, Vilaró, M., additional, Tabernero, J., additional, and Rodon, J., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results